Shots: TULIP 1 P-III trial with didn’t meet SRI4@12mos in moderate-to-severe SLE patients TULIP study includes two P-III trials TULIP 1 (N=460) in ratio (1:2:2) for 52 wks. administering of 150,300mg anifrolumab IV or PBO q4w; TULIP 2(N=373) in ratio (1:1) 300mg anifrolumab IV or PBO q4w, evaluating safety and efficacy Anifrolumab is also being […]Read More
